Academic Journal
Next-Generation vaccine adjuvants: NIAID perspective on mechanistic insights and emerging strategies.
| Τίτλος: | Next-Generation vaccine adjuvants: NIAID perspective on mechanistic insights and emerging strategies. |
|---|---|
| Συγγραφείς: | Kelly HR; Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. Electronic address: Halonna.kelly@nih.gov., Leitner WW; Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. |
| Πηγή: | Current opinion in virology [Curr Opin Virol] 2026 Sep; Vol. 76, pp. 101553. Date of Electronic Publication: 2026 May 05. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101560941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-6265 (Electronic) Linking ISSN: 18796257 NLM ISO Abbreviation: Curr Opin Virol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Elsevier |
| Ιατρικοί όροι (MeSH): | Vaccines*/immunology , Adjuvants, Immunologic* , Adjuvants, Vaccine* , Vaccine Development*, Humans ; Animals ; National Institute of Allergy and Infectious Diseases (U.S.) ; United States ; Immunity, Innate ; Vaccinology |
| Περίληψη: | Vaccine adjuvants play a central role in shaping the magnitude, quality, and durability of vaccine-induced immune responses, yet their rational design and selection remain major challenges. Although the adjuvant repertoire has expanded substantially over the past two decades, this growth has not yielded broadly predictive frameworks capable of matching adjuvants to antigens, vaccine platforms, disease contexts, or populations. Advances in innate immunology and systems vaccinology have revealed early immune signatures associated with vaccine efficacy, but translating these insights into generalizable design rules has proven difficult due to context dependence, population heterogeneity, and the complexity of immune pathways. To address these limitations, the Division of Allergy, Immunology, and Transplantation (DAIT) within the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health, has established coordinated adjuvant discovery, development, and comparative research programs that emphasize standardized study designs, harmonized immune profiling, and cross-platform data integration that enable the systematic evaluation of adjuvant mechanisms and biological activities. Here, we examine conceptual and practical lessons emerging from DAIT/NIAID-supported programs and the adjuvant field more broadly, focusing on comparative immune profiling, adjuvant mimics, and combination adjuvants. Collectively, these efforts illustrate how harmonized datasets, shared infrastructure, and mechanism-guided analyses can transform adjuvant selection from an empirical process into a data-driven component of rational vaccine design, supporting precision immunomodulation across infectious, immunologic, and other non-infectious diseases. (Published by Elsevier B.V.) |
| Competing Interests: | Declaration of Competing Interest The authors declare no competing interests. |
| Grant Information: | Z99 AI999999 United States ImNIH Intramural NIH HHS |
| Substance Nomenclature: | 0 (Adjuvants, Immunologic) 0 (Adjuvants, Vaccine) 0 (Vaccines) |
| Entry Date(s): | Date Created: 20260506 Date Completed: 20260814 Latest Revision: 20260814 |
| Update Code: | 20260815 |
| PubMed Central ID: | PMC13395248 |
| DOI: | 10.1016/j.coviro.2026.101553 |
| PMID: | 42090823 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!